Synergistic growth inhibition by combination of adenovirus mediated p53 transfer and cisplatin in ovarian cancer cell lines

Journal of Gynecologic Oncology

Volumn 20, Issue 1, 2009, Pages 48-54

  Ryu, Sang Young ^a   Kim, Kidong ^a   Lee, Woo Sik ^a   Kwon, Hee Chung ^a   Lee, Kee Ho ^a   Kim, Chang Min ^b   Kang, Soon Beom ^c  

^a Korea Cancer Center Hospital   (South Korea)

^b National Cancer Center   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Adenoviruses; Cisplatin; Gene therapy; P53

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CELL COUNT; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN OVCAR 3; CELL STRAIN PA1; CELL STRAIN SKOV3; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE SEQUENCE; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; GENE MUTATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; OVARY CANCER; PLOIDY; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; WILD TYPE;

EID: 77953458791     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2009.20.1.48     Document Type: Article

References (36)

1. Ozols RF, Schwartz PE, Eifel PJ, Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principle and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers; 1997. p.1502-39.
2. Pecorelli S, Odicino F, Maisonneuve P Creasman W, Shepard J, Sideri M, et al. Carcinoma of the ovary. J Epidemiol Biostat 1998; 3: 75-102.
3. Hamilton TC, Johnson SW, Godwin AK. Molecular biology of gynecologic malignancies. In: Ozols RF, editor. Gynecologic oncology. 1st ed. Boston: Kluwer Academic Publisher, 1998. p.103-14.
4. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993; 85: 1513-9.
5. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 1993; 90: 4961-5.
6. Berchuck A, Kohler MF, Bast RC Jr. Molecular genetic features of ovarian cancer. Prog Clin Biol Res 1996; 394: 269-84.
7. Chen PL, Chen YM, Bookstein R, Lee WH. Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990; 250: 1576-80.
8. Williams GT, Smith CA. Molecular regulation of apoptosis: Genetic controls on cell death. Cell 1993; 74: 777-9.
9. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A 1992; 89: 4495-9.
10. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995; 55: 5151-5.
11. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2: 985-91.
12. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 1996; 12: 1617-23.
13. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996; 10: 1945-52.
14. von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS, Mathis JM. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer. Gynecol Oncol 1998; 69: 197-204.
15. Yang B, Eshleman JR, Berger NA, Markowitz SD. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 1996; 2: 1649-57.
16. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54: 2287-91.
17. Kanamori Y, Kigawa J, Minagawa Y, Irie T, Oishi T, Shimada M, et al. A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Eur J Cancer 1998; 34: 1802-6.
18. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13: 1589-99.
19. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia. Lancet 1987; 2: 353-9.
20. Ogawa N, Fujiwara T, Kagawa S, Nishizaki M, Morimoto Y, Tanida T, et al. Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int J Cancer 1997; 73: 367-70.
21. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 1996; 112: 1372-6.
22. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, et al. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 1996; 122: 360-5.
23. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, et al. A p53-dependent mouse spindle checkpoint. Science 1995; 267: 1353-6.
24. Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995; 14: 3-15.
25. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381: 713-6.
26. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-501.
27. Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci U S A 1998; 95: 13692-7.
28. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992; 52: 4196-9.
29. Graham FL, Smiley J, Russell WC, Naim R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
30. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1989.
31. Kanegae Y, Makimura M, Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol 1994; 47: 157-66.
32. Tang DC, Johnston SA, Carbone DP. Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. Cancer Gene Ther 1994; 1: 15-20.
33. Skehan P. Cytotoxicity and cell growth assays. In: Julio EC, editor. Cell biology. 2nd ed. San Diego: Academic Press; 1998. p.313-8.
34. Juan G, Darzynkiewicz Z. Cell cycle analysis by flow and laser scanning cytometry. In: Julio EC, editor. Cell biology. 2nd ed. San Diego: Academic Press; 1998. p.261-74.
35. Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994; 1: 5-13.
36. Roemer K, Friedmann T. Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function. Ann N Y Acad Sci 1994; 716: 265-80.